Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
A U GerberU Greter

Abstract

A granulocytopenic mouse model was used to elucidate the impact of dose spacing on the activity of netilmicin against Pseudomonas aeruginosa. A thigh infection was produced and then treated with netilmicin combined with azlocillin. Netilmicin was injected subcutaneously at decreasing doses every 20 min to result in plasma-concentration-time curves similar to those observed in patients on intravenous netilmicin treatment. A once-daily regimen was simulated and compared to a simulated conventional schedule of every 8 h. Identical total amounts of drug were used in both groups of comparatively treated mice. Therapeutic efficacy was quantitated by repeated determinations of surviving organisms in thigh homogenates. Combination therapy was significantly more effective than azlocillin treatment alone. In combination regimens the simulated once-daily netilmicin schedule killed the target organisms faster than the simulated thrice-daily regimen and was significantly more efficacious by 24 and 32 h in two out of three strains of Pseudomonas aeruginosa tested. It is concluded that the results of combination therapy of severe Pseudomonas aeruginosa infections in the immunocompromised host might be improved by choosing an aminoglycoside do...Continue Reading

References

Dec 1, 1979·The Journal of Infectious Diseases·J E Pennington, R M Stone
Jul 1, 1978·Antimicrobial Agents and Chemotherapy·G HumbertG Oksenhendler
Feb 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
Oct 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
Mar 1, 1988·Antimicrobial Agents and Chemotherapy·G L Drusano
Mar 1, 1988·The Journal of Antimicrobial Chemotherapy·L Mizen, G Woodnutt
Dec 1, 1971·The Journal of Infectious Diseases·G G Jackson, L J Riff
Dec 1, 1984·European Journal of Clinical Microbiology·A U GerberH P Brugger
Mar 1, 1984·Annals of Internal Medicine·R D MooreP S Lietman
Jan 1, 1981·Reviews of Infectious Diseases·R W BundtzenW A Craig
Apr 1, 1982·The Journal of Infectious Diseases·A U GerberG Lebek
Nov 1, 1982·The Journal of Infectious Diseases·A U GerberW A Craig

❮ Previous
Next ❯

Citations

Jun 1, 1995·Journal of Chemotherapy·W A Craig
Oct 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R RoosendaalB M Michel
Dec 7, 2010·The Journal of Antimicrobial Chemotherapy·Michael N MavrosMatthew E Falagas
May 15, 2002·The Pediatric Infectious Disease Journal·Alok RastogiRosita S Pildes
Feb 10, 1996·BMJ : British Medical Journal·M BarzaJ Lau
Jan 1, 1990·Intensive Care Medicine·I A Bakker-Woudenberg, R Roosendaal
May 1, 1994·Intensive Care Medicine·B P Wagner, J Pfenninger
Aug 1, 1995·Journal of Chemotherapy·G Gialdroni Grassi
Jul 21, 2012·Parasitology·Yasmin SultanaRogan Lee
Dec 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J Blaser, C König

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.